N-terminal pro brain natriuretic peptide and cardiac function in doxorubicin administered pediatric patients

Journal of the Medical Association of Thailand

Volumn 92, Issue 11, 2009, Pages 1450-1457

  Hongkan, Wasana ^a   Soongswang, Jarupim ^a   Veerakul, Gavivann ^a   Sanpakit, Kleebsabai ^a   Punlee, Kesaree ^a   Rochanasiri, Wandee ^a   Udompunturak, Suthipol ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Diastolic dysfunction; Doxorubicin induced cardiomyopathy; Serum NT pro BNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; DOXORUBICIN; ANTINEOPLASTIC ANTIBIOTIC; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; ASSOCIATION; CANCER PATIENT; CARDIOMYOPATHY; CHILD; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE FUNCTION; HEPATOBLASTOMA; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; OSTEOSARCOMA; SARCOMA; THORAX RADIOGRAPHY; ANALYSIS OF VARIANCE; BLOOD; CHEMICALLY INDUCED DISORDER; CROSS-SECTIONAL STUDY; ELECTROCARDIOGRAPHY; HEART FUNCTION TEST; NONPARAMETRIC TEST;

ANALYSIS OF VARIANCE; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL MARKERS; CHILD; CROSS-SECTIONAL STUDIES; DOXORUBICIN; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART FUNCTION TESTS; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; RADIOGRAPHY, THORACIC; STATISTICS, NONPARAMETRIC; VENTRICULAR DYSFUNCTION;

EID: 75349083859     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869-79.
2. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-7.
3. Dreyer ZE, Mahoney DH, McClain KL, Poplack DG. Hematologic issues of importance for the pediatric cardiologist. In: Garson A, Bricker JT, Fisher DJ, Neish SR, editors. The science and practice of pediatric cardiology. 2nd ed. Baltimore: Williams & Wilkins; 1998: 2745-9.
4. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342: 1077-84.
5. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339: 900-5.
6. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004; 109: 3122-31.
7. Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 1992; 89: 942-9.
8. Bu'Lock FA, Mott MG, Oakhill A, Martin RP. Left ventricular diastolic filling patterns associated with progressive anthracycline-induced myocardial damage: A prospective study. Pediatr Cardiol 1999; 20: 252-63.
9. Ewer MS, Ali MK, Gibbs HR, Swafford J, Graff KL, Cangir A, et al. Cardiac diastolic function in pediatric patients receiving doxorubicin. Acta Oncol 1994; 33: 645-9.
10. Marchandise B, Schroeder E, Bosly A, Doyen C, Weynants P, Kremer R, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989; 118: 92-8.
11. Nousiainen T, Vanninen E, Jantunen E, Puustinen J, Remes J, Rantala A, et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med 2002; 251: 228-34.
12. Schwachtgen L, Herrmann M, Georg T, Schwarz P, Marx N, Lindinger A. Reference values of NTproBNP serum concentrations in the umbilical cord blood and in healthy neonates and children. Z Kardiol 2005; 94: 399-404.
13. Sung RY, Huang GY, Shing MK, Oppenheimer SJ, Li CK, Li CK, et al. Echocardiographic evaluation of cardiac function in paediatric oncology patients treated with or without anthracycline. Int J Cardiol 1997; 60: 239-48.
14. Gardner DG. Natriuretic peptides: markers or modulators of cardiac hypertrophy? Trends Endocrinol Metab 2003; 14: 411-6.
15. Benvenuto GM, Ometto R, Fontanelli A, Fortunato A, Ruffini PA, Fosser V, et al. Chemotherapyrelated cardiotoxicity: new diagnostic and preventive strategies. Ital Heart J 2003; 4: 655-67.
16. Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 2002; 4: 235-42.
17. Horacek JM, Pudil R, Tichy M, Jebavy L, Strasova A, Praus R, et al. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma 2005; 52: 430-4.
18. Okumura H, Iuchi K, Yoshida T, Nakamura S, Takeshima M, Takamatsu H, et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 2000; 104: 158-63.
19. Suzuki T, Hayashi D, Yamazaki T, Mizuno T, Kanda Y, Komuro I, et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998; 136: 362-3.
20. Tang WHW, Lee MJ, Van Lente F, Francis GS. Sequential plasma B-type natriuretic peptide and N-terminal pro-BNP: How does their performance differ? Abstracts from the 2003 Scientific Sessions of the American Heart Association. November 9-12, 2003, Orlando, Florida, USA. Circulation. 2003; 108 (17 Suppl): IV334.
21. Triepels RH, Busscher S, van der Burgh PH, Vermes I. N-terminal pro-brain natriuretic peptide (NT-pro BNP) as screening test for early stage heart failure. Clin Chem 2003; 49: A37-8.
22. Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 2001; 37: 4-9.
23. Poutanen T, Tikanoja T, Riikonen P, Silvast A, Perkkio M. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol 2003; 21: 2349-56.
24. O'leary PW. Pediatric diastology: use and limitations of Doppler echocardiography in the evaluation of ventricular diastolic function in children. Prog Pediatr Cardiol 1999; 10: 83-93
25. Ganz WI, Sridhar KS, Ganz SS, Gonzalez R, Chakko S, Serafini A. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 1996; 53: 461-70.
26. Wang SQ. Electrocardiogram analysis of adriamycin cardiotoxicity in 160 cases. Zhonghua Zhong Liu Za Zhi 1991; 13: 71-3.
27. Koulouri S, Acherman RJ, Wong PC, Chan LS, Lewis AB. Utility of B-type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric patients with respiratory distress. Pediatr Cardiol 2004; 25: 341-6.
28. Soker M, Kervancioglu M. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med J 2005; 26: 1197-202.
29. Germanakis I, Kalmanti M, Parthenakis F, Nikitovic D, Stiakaki E, Patrianakos A, et al. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. Int J Cardiol 2006; 108: 212-5.
30. Dorup I, Levitt G, Sullivan I, Sorensen K. Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function. Heart 2004; 90: 1214-6.
31. Iarussi D, Galderisi M, Ratti G, Tedesco MA, Indolfi P, Casale F, et al. Left ventricular systolic and diastolic function after anthracycline chemotherapy in childhood. Clin Cardiol 2001; 24: 663-9.
32. Koseoglu V, Berberoglu S, Karademir S, Kismet E, Yurttutan N, Demirkaya E, et al. Cardiac troponin I: is it a marker to detect cardiotoxicity in children treated with doxorubicin? Turk J Pediatr 2005; 47: 17-22.
33. Benvenuto GM, Morandi P, Merlini L, Fortunato A, Ometto R, Fontanelli A. Anthracyclines cardiotoxicity monitoring by conventional echo-Doppler and tissue Doppler imaging: its relationship with pro-brain natriuretic peptide. Eur J Echocardiogr 2003; 4 (Suppl 1): S37.
34. Pinarli FG, Oguz A, Tunaoglu FS, Karadeniz C, Gokcora N, Elbeg S. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatr Blood Cancer 2005; 44: 370-7.
35. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracyclineinduced myocardial damage: a review of the most promising strategies. Br J Haematol 2005; 131: 561-78.